Q3 Earnings Estimate for KYMR Issued By HC Wainwright

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Kymera Therapeutics in a research report issued on Friday, February 28th. HC Wainwright analyst A. Fein expects that the company will post earnings per share of ($0.75) for the quarter. HC Wainwright currently has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($0.75) EPS and FY2029 earnings at ($0.57) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The business had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%.

Other research analysts also recently issued reports about the stock. Morgan Stanley increased their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an "equal weight" rating in a research report on Wednesday, November 6th. Stephens restated an "overweight" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. UBS Group dropped their price target on Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. Wells Fargo & Company raised Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $38.00 to $57.00 in a report on Monday, December 2nd. Finally, Leerink Partners restated an "outperform" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Friday, December 27th. Three research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Kymera Therapeutics has an average rating of "Moderate Buy" and an average price target of $56.69.

Kymera Therapeutics Stock Down 3.8 %

NASDAQ KYMR traded down $1.18 during trading hours on Monday, reaching $30.17. 982,064 shares of the company were exchanged, compared to its average volume of 578,939. The stock has a market capitalization of $1.95 billion, a P/E ratio of -12.89 and a beta of 2.18. Kymera Therapeutics has a 1 year low of $29.16 and a 1 year high of $53.27. The business's 50 day simple moving average is $39.02 and its 200-day simple moving average is $43.75.

Institutional Investors Weigh In On Kymera Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. increased its stake in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock worth $114,000 after acquiring an additional 504 shares during the last quarter. Harbor Capital Advisors Inc. increased its position in shares of Kymera Therapeutics by 30.0% in the third quarter. Harbor Capital Advisors Inc. now owns 40,303 shares of the company's stock worth $1,908,000 after purchasing an additional 9,292 shares during the last quarter. Natixis Advisors LLC bought a new position in shares of Kymera Therapeutics in the third quarter worth approximately $681,000. Thrivent Financial for Lutherans purchased a new stake in Kymera Therapeutics in the third quarter valued at approximately $313,000. Finally, Jennison Associates LLC lifted its position in Kymera Therapeutics by 85.8% during the third quarter. Jennison Associates LLC now owns 797,681 shares of the company's stock valued at $37,754,000 after purchasing an additional 368,394 shares during the last quarter.

Insider Buying and Selling

In other news, insider Ellen Chiniara sold 3,129 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the transaction, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. The trade was a 5.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.82% of the stock is currently owned by insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.